
Oncology NEWS International
- Oncology NEWS International Vol 5 No 5
- Volume 5
- Issue 5
Zeneca Acquires US Rights to Kadian, an Oral Morphine Product
WILMINGTON, Del--Zeneca Inc. has reached an agreement with Faulding Services Inc. (Adelaide, South Australia) for exclusive US rights to purchase, distribute, and promote Faulding's sustained-release morphine sulfate product Kadian, an oral medication taken once or twice daily.
WILMINGTON, Del--Zeneca Inc. has reached an agreement with FauldingServices Inc. (Adelaide, South Australia) for exclusive US rightsto purchase, distribute, and promote Faulding's sustained-releasemorphine sulfate product Kadian, an oral medication taken onceor twice daily.
A new drug application (NDA) for use of Kadian in the treatmentof moderate to severe chronic pain is currently under FDA review.The product is approved and available in Australia and severalEuropean countries.
Articles in this issue
almost 30 years ago
No Need to Delay Mammography After FNA, Study Showsalmost 30 years ago
Pediatric Cancer Guidelines Are a National Effortalmost 30 years ago
EPA Proposes Changes in Determining Cancer Risk of Chemicals, Pollutantsalmost 30 years ago
ATL's HDI Digital Ultrasound Is Approved for Breast Indicationalmost 30 years ago
NIH Study Suggests That 200 mg Is The Optimal Daily Dose of Vitamin Calmost 30 years ago
Natural History of HIV Supports the Use Of Early Interventionsalmost 30 years ago
Aids Vaccine Trial Fails to Show Clinical Benefitalmost 30 years ago
Rep. Porter Honored For Work on BudgetNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































